TENX Tenax Therapeutics, Inc.
Tenax Therapeutics, Inc. (TENX) is expected to report earnings on February 4, 2027, before the market open. The consensus earnings estimate is a loss of $0.37 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -19.8% since its last earnings release on November 5, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Tenax Therapeutics, Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company. The Company is engaged in developing & commercializing pharmaceutical products for critical care patients. Its products include; Levosimendan and Oxycyte.
Sector
Healthcare
Industry
Biotechnology
Charts powered in part by Lightweight Charts™ by TradingView.